Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00513
|
|||||
| Drug Name |
Sulfinpyrazone
|
|||||
| Synonyms |
(+/-)-SULFINPYRAZONE; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin [German]; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl) pyrazolidine; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine; 1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-[2-(phenylsulfinyl)ethyl-3,5-pyrazolidinedione; 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione; 4-(2-Benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione; 4-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione; 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione; Anturan; Anturane; Anturane (TN); Anturanil; Anturano; Anturen; Anturidin; Apo Sulfinpyrazone; Apo-Sulfinpyrazone; Apotex Brand of Sulfinpyrazone; Diphenylpyrazone; Enturan; Enturen; G 28,315; G 28315; Novartis Brand of Sulfinpyrazone; Novopyrazone; Nu Pharm Brand of Sulfinpyrazone; Nu Sulfinpyrazone; Nu-Pharm Brand of Sulfinpyrazone; Nu-Sulfinpyrazone; Sulfinpirazona; Sulfinpirazona [INN-Spanish]; Sulfinpyrazine; Sulfinpyrazon; Sulfinpyrazone (JP15/USP/INN); Sulfinpyrazone (SPZ); Sulfinpyrazone [USAN:INN:JAN]; Sulfinpyrazonum; Sulfinpyrazonum [INN-Latin]; Sulfoxyphenylpyrazolidin; Sulfoxyphenylpyrazolidine; Sulphinpyrazone; USAF GE-13
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Arthritis [ICD11: FA5Z] | Approved | [1] | |||
| Gout [ICD11: FA25] | Approved | [1] | ||||
| Therapeutic Class |
Uricosuric Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C23H20N2O3S
|
|||||
| Canonical SMILES |
C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4
|
|||||
| InChI |
InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
|
|||||
| InChIKey |
MBGGBVCUIVRRBF-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 57-96-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 404.5 | Topological Polar Surface Area | 76.9 | ||
| Heavy Atom Count | 29 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321460
, 11112139
, 11335265
, 11360504
, 11363916
, 11366478
, 11369040
, 11371640
, 11374587
, 11377202
, 11461476
, 11466318
, 11467438
, 11485183
, 11486155
, 11489140
, 11490406
, 11492660
, 11494836
, 117338
, 14718483
, 14879380
, 24899841
, 26611933
, 26680609
, 26747070
, 26747071
, 29224394
, 46500625
, 46504918
, 47216628
, 47290983
, 47290984
, 47440092
, 47588838
, 48110300
, 48334323
, 48416577
, 49698736
, 50029653
, 50100985
, 50661502
, 53789714
, 5632696
, 611476
, 7847515
, 8149541
, 8153281
, 855982
, 9525
|
|||||
| ChEBI ID |
ChEBI:9342
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| References | ||||||
| 1 | Sulfinpyrazone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.